Talk to the Institute
Published mark

Allogene Therapeutics, Inc.

NASDAQ: ALLO. Canonical company identity and public leadership record.

US

Record source reportedRecord not claimedNo Eval published
Follow companySave PDF
Alpha ID
alpha:company:0cdb3d9c-5598-43da-aed5-36b4bc6058b9
SEC CIK
0001737287
Record version
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 16, 2026
Newest evidence
May 3, 2026
Monitoring
Not yet monitored Details
Integrity
Not yet signed Methodology
CEO
Derek ChangSince Apr 30, 2026
Chair
Not published
Independent
8 / 1111 directors published
Published claims
274 distinct sources
Evidence records
70 pinned
Source conflicts
0None open

Built from 4 distinct sources and 7 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.

CorroboratedSource reportedAlpha inferenceNot disclosed

Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works

CEO CHANGED

Derek Chang executive of Allogene Therapeutics, Inc., effective 2026-04-30.

EffectiveEffective Apr 30, 2026E4

Monitoring

Continuous

What the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.

  • Identityunclaimed
    Published
  • Evidencesource_reported
    Published
  • Evaluationnot_evaluated
    Published
  • MonitoringNot yet published for this record.
    Not published
  • AuthorityNot yet published for this record.
    Not published
  • Freshnesscurrent
    Published

Leadership

Evidence
RolePersonSinceStatusClaim
President and Chief Executive OfficerDerek ChangApr 2026currentSource reportedE4
Senior Vice President, General Counsel and Corporate SecretaryEarl DouglasApr 2026currentSource reportedE5
Chief Financial OfficerGeoffrey ParkerApr 2026currentSource reportedE6
President and Chief Executive OfficerDavid Chang, M.D., Ph.D.Not capturedunknownSource reportedE3

Board of directors

Evidence

11 directors published. 8 of 11 with a published determination are independent.

DirectorStatusSinceCommitteesClaim
Arie Belldegrun, M.D.Not independent2017None publishedSource reportedE2
David Chang, M.D., Ph.D.Not independent2018None publishedSource reportedE2
Deborah MessemerIndependent2018Audit, chairAudit · Chair; Nominating and Governance · ChairNominating and Governance, chairSource reportedE2
Elizabeth BarrettIndependent2021AuditSource reportedE2
Franz Humer, Ph.D.Independent2018None publishedSource reportedE2
John DeYoungIndependent2018CompensationSource reportedE2
Joshua KazamNot independent2017None publishedSource reportedE2
Owen Witte, M.D.Independent2018None publishedSource reportedE2
Stephen Mayo, Ph.D.Independent2022None publishedSource reportedE2
Todd SisitskyIndependent2018Nominating and GovernanceSource reportedE2
Vicki Sato, Ph.D.Independent2021None publishedSource reportedE2

Committees and risk ownership

Evidence
CommitteeChairMembersRisks assigned
AuditDeborah MessemerDeborah Messemer, Elizabeth BarrettNot described in the published record
Audit · Chair; Nominating and Governance · ChairNot publishedDeborah MessemerNot described in the published record
CompensationNot publishedJohn DeYoungNot described in the published record
Nominating and GovernanceDeborah MessemerDeborah Messemer, Todd SisitskyNot described in the published record
Committee RecordAudit: Chair Deborah Messemer; Members Deborah Messemer (Chair); Elizabeth Barrett
Source reportedE7
company:0cdb3d9c-5598-43da-aed5-36b4bc6058b9:committee_record:20
Committee AppointmentDeborah Messemer: chair, Audit
Source reportedE7
company:0cdb3d9c-5598-43da-aed5-36b4bc6058b9:committee_appointment:21
Committee AppointmentElizabeth Barrett: member, Audit
Source reportedE7
company:0cdb3d9c-5598-43da-aed5-36b4bc6058b9:committee_appointment:22
Committee RecordCompensation: Chair not stated; Members John DeYoung
Source reportedE7
company:0cdb3d9c-5598-43da-aed5-36b4bc6058b9:committee_record:23
Committee AppointmentJohn DeYoung: member, Compensation
Source reportedE7
company:0cdb3d9c-5598-43da-aed5-36b4bc6058b9:committee_appointment:24
Committee RecordNominating and Governance: Chair Deborah Messemer; Members Deborah Messemer (Chair); Todd Sisitsky
Source reportedE7
company:0cdb3d9c-5598-43da-aed5-36b4bc6058b9:committee_record:25
Committee AppointmentDeborah Messemer: chair, Nominating and Governance
Source reportedE7
company:0cdb3d9c-5598-43da-aed5-36b4bc6058b9:committee_appointment:26
Committee AppointmentTodd Sisitsky: member, Nominating and Governance
Source reportedE7
company:0cdb3d9c-5598-43da-aed5-36b4bc6058b9:committee_appointment:27

Control and voting power

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Authority to act

Evidence and agent registry

Who can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.

Principal executive officerDerek Chang, President and Chief Executive Officer, from Apr 30, 2026
Source reportedE4
company:0cdb3d9c-5598-43da-aed5-36b4bc6058b9:leadership_role:17
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
bind
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
agents
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
delegations

Financials and market context

Evidence
Security ListingALLO (NASDAQ)
Source reportedE1
company:0cdb3d9c-5598-43da-aed5-36b4bc6058b9:security_listing:28
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 16, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.

Governance and policies

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Risk, audit, and cyber

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

AI oversight and accountability

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Compensation

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Other published claims

Evidence

Published Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.

Legal NameAllogene Therapeutics, Inc.
Source reportedE1
company:0cdb3d9c-5598-43da-aed5-36b4bc6058b9:legal_name:1
Entity StatusPublic listing published
Source reportedE1
company:0cdb3d9c-5598-43da-aed5-36b4bc6058b9:entity_status:3

Not yet in this record

Coverage

A gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.

  • Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
  • OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
  • FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
  • CompensationNot reviewed. Pay design shows how incentives are governed.
  • GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
  • Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
  • AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
  • LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
  • RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
  • CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
  • AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
  • Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
  • Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
  • Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
  • Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
  • Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
  • This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.

Subject and corrections

Public-role doctrine

This record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.

Basis
Published company record built from public sources
Sources
7 evidence records cited. 0 with redistribution rights.
Never published
Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
Record claimed
No
Open disputes
0
Identity ownership
unclaimed
Claiming not yet available

If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.

Evidence

Authority and rights
  1. E1
    Alpha canonical company public projection
    Alpha canonical company public projection. canonical identity. Retrieved Oct 16, 2026. Cited by 4 Claims.
    Open web
    Rights not recorded, link only
    Evidence not pinned
  2. E2
    Allogene Therapeutics, Inc. DEF 14A 2025-04-30
    sec proxy. Published Apr 30, 2025. Retrieved Apr 24, 2026. Cited by 11 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  3. E3
    ALLO executive roster source
    sec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
    Authority not assessed
    Rights not recorded, link only
    Evidence not pinned
  4. E4
    ALLO DEF 14A executive officers
    sec filing. Published Apr 30, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  5. E5
    ALLO DEF 14A executive officers
    sec filing. Published Apr 30, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  6. E6
    ALLO DEF 14A executive officers
    sec filing. Published Apr 30, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  7. E7
    Audit
    board_seats. board seats. Cited by 8 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned

What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 16, 2026
  • Derek Chang executive of Allogene Therapeutics, Inc., effective 2026-04-30.
  • Earl Douglas executive of Allogene Therapeutics, Inc., effective 2026-04-30.
  • Geoffrey Parker executive of Allogene Therapeutics, Inc., effective 2026-04-30.
  • Stephen Mayo, Ph.D. seat on Allogene Therapeutics, Inc., effective 2022-01-01.
  • Elizabeth Barrett seat on Allogene Therapeutics, Inc., effective 2021-01-01.
  • Vicki Sato, Ph.D. seat on Allogene Therapeutics, Inc., effective 2021-01-01.
  • Elizabeth Barrett member of Audit, effective 2021-01-01.
  • David Chang, M.D., Ph.D. seat on Allogene Therapeutics, Inc., effective 2018-01-01.
  • Deborah Messemer seat on Allogene Therapeutics, Inc., effective 2018-01-01.
  • Franz Humer, Ph.D. seat on Allogene Therapeutics, Inc., effective 2018-01-01.
  • John DeYoung seat on Allogene Therapeutics, Inc., effective 2018-01-01.
  • Owen Witte, M.D. seat on Allogene Therapeutics, Inc., effective 2018-01-01.
  • Todd Sisitsky seat on Allogene Therapeutics, Inc., effective 2018-01-01.
  • Audit · Chair; Nominating and Governance · Chair committee of Allogene Therapeutics, Inc., effective 2018-01-01.
  • Deborah Messemer member of Audit · Chair; Nominating and Governance · Chair, effective 2018-01-01.
  • John DeYoung member of Compensation, effective 2018-01-01.
  • Todd Sisitsky member of Nominating and Governance, effective 2018-01-01.
  • Arie Belldegrun, M.D. seat on Allogene Therapeutics, Inc., effective 2017-01-01.
  • Joshua Kazam seat on Allogene Therapeutics, Inc., effective 2017-01-01.
Appearance

Alpha Governance PBC. The Registry records reported facts and Alpha's assessments separately. A missing fact is not evidence that it is false.

Record alpha:company:0cdb3d9c-5598-43da-aed5-36b4bc6058b9, version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce. https://registry.alpha.ac/companies/allogene-therapeutics-inc

Navigate

On this record

  1. Overview
  2. Monitoring4
  3. Leadership4
  4. Board11
  5. Committees4
  6. Control and voting0
  7. Authority to act4
  8. Financials1
  9. Governance0
  10. Risk0
  11. AI oversight0
  12. Legal0
  13. Compensation0
  14. Other published claims3
  15. Coverage gaps17
  16. Linked people15
  17. Subject and corrections6
  18. Evidence7
  19. Version historyvpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

Linked records

Registry

Appearance

esc
  • Actions
    Switch to agent viewJSON, Markdown, MCP
  • Copy Alpha IDalpha:company:0cdb3d9c-5598-43da-aed5-36b4bc6058b9
  • Cite this recordAllogene Therapeutics, Inc.
  • Copy canonical URLregistry.alpha.ac/companies/allogene-therapeutics-inc
  • Copy as MarkdownWith assertion states
  • Report an error
  • Theme: System
  • Theme: Light
  • Theme: Dark
  • Records
    Allogene Therapeutics, Inc.Company
  • Derek ChangPerson
  • Earl DouglasPerson
  • Geoffrey ParkerPerson
  • David Chang, M.D., Ph.D.Person
  • Arie Belldegrun, M.D.Person
  • David Chang, M.D., Ph.D.Person
  • Deborah MessemerPerson
  • Elizabeth BarrettPerson
  • Franz Humer, Ph.D.Person
  • John DeYoungPerson
  • Joshua KazamPerson
  • Owen Witte, M.D.Person
  • Stephen Mayo, Ph.D.Person
  • Todd SisitskyPerson
  • Vicki Sato, Ph.D.Person
  • Sections
    OverviewAllogene Therapeutics, Inc.
  • MonitoringAllogene Therapeutics, Inc.
  • LeadershipAllogene Therapeutics, Inc.
  • BoardAllogene Therapeutics, Inc.
  • CommitteesAllogene Therapeutics, Inc.
  • Control and votingAllogene Therapeutics, Inc.
  • Authority to actAllogene Therapeutics, Inc.
  • FinancialsAllogene Therapeutics, Inc.
  • GovernanceAllogene Therapeutics, Inc.
  • RiskAllogene Therapeutics, Inc.
  • AI oversightAllogene Therapeutics, Inc.
  • LegalAllogene Therapeutics, Inc.
  • CompensationAllogene Therapeutics, Inc.
  • Other published claimsAllogene Therapeutics, Inc.
  • Coverage gapsAllogene Therapeutics, Inc.
↑ ↓ move↵ openThis record only

Report an error

Reports attach to the Claim and go to an Alpha analyst through the correction form. Corrections are versioned, and the original stays in history.